849833-55-2

Basic information

• Product Name: (1Z)-N'-hydroxypropanimidamide
• Synonyms: (1Z)-N'-hydroxypropanimidamide
• CAS NO: 849833-55-2
• Molecular Formula: C₃H₈N₂O
• Molecular Weight: 88.10842
• Mol File: 849833-55-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 24-25 °C
• Boiling Point: 132.8±23.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• PKA: 7.48±0.69(Predicted)
• CAS DataBase Reference: (1Z)-N'-hydroxypropanimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: (1Z)-N'-hydroxypropanimidamide(849833-55-2)
• EPA Substance Registry System: (1Z)-N'-hydroxypropanimidamide(849833-55-2)

Safety Data

• Hazardous Substances Data: 849833-55-2(Hazardous Substances Data)

Upstream product

• 107-12-0 propiononitrile 

Downstream Products

• 721952-76-7 3-{3-[4-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl]propyl}-5,5-bis(4-fluorophenyl)-2-methyl-3,5-dihydro-4H-imidazol-4-one 
• 22354-96-7 3-ethyl-5-phenyl-1,2,4-oxadiazole 
• 1035263-85-4 4-[(4-Chlorophenyl)methyl]-2-({(2R)-1-[2-(3-ethyl-1,2,4-oxadiazol-5-yl)ethyl]-2-pyrrolidinyl}methyl)pyrido[3,4-d]pyridazin-1(2H)-one 
• 1204315-98-9 4-{3-[1-(3-ethyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]propoxy}-2-methyl-benzoic acid methyl ester 
• 1163127-01-2 1-((3-ethyl-[1,2,4]oxadiazol-5-yl)(phenyl)methyl)-4-(2-fluoro-4-nitrophenyl)piperazine 
• 1163248-70-1 5-(4-bromo-3-fluorophenyl)-3-ethyl-[1,2,4]oxadiazole 
• 1046536-29-1 C₁₈H₃₁N₃O₄ 
• 50737-34-3 5-chloromethyl-3-ethyl-[1,2,4]oxadiazole 
• 1596358-16-5 3-ethyl-5-(4'-nitrophenyl)-1,2,4-oxadiazole 

Relevant articles and documents

Optimization of Novel 1-Methyl-1 H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm

A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 μM. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 μM. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 μM.

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

FUSED HETEROCYCLIC RING COMPOUND

A compound represented by the following formula or a salt thereof, which has an GPR119 agonist action, is useful for the prophylaxis or treatment of diabetes, obesity and the like, and shows superior efficacy: wherein P: substituted 6-membered aromatic ring, Q: (substituted) 6-membered aromatic ring, A1: CR4aR4b, NR4c, O, S, SO or SO2 {R4a-4c: H etc.}, L1: (substituted) C1-5 alkylene, L2: a bond or (substituted) C1-3 alkylene, L3-4: (substituted) C1-3 alkylene, R1: H, X, CN, (substituted) hydrocarbon, (substituted) heterocycle or (substituted) OH, or (substituted) 4- to 8-membered (heterocyclic) ring together with A1, R2: H, CN, (substituted) hydrocarbon, and R3a: -COSRA1, (substituted) 5- or 6-membered aromatic ring {RA1: (substituted) hydrocarbon or (substituted) heterocycle}.